Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

expenses totaled $7.3 million in the fourth quarter of 2010, compared to $6.5 million in the fourth quarter of 2009, and $27.9 million in the full year ended December 31, 2010, compared to $25.2 million in the full year ended December 31, 2009. This increase is primarily attributable to expenses related to litigation and increased patent fees. General and administrative expenses in the full year ended December 31, 2010, included $2.1 million in non-cash, share-based compensation expense, compared to $2.8 million in 2009.

Total interest and other expense increased to $28.2 million in the full year ended December 31, 2010, compared to $14.8 million in 2009. This increase is primarily attributable to increases in the loss on extinguishment of debt, a non-cash item, and interest expense, both related to Arena's loan from certain Deerfield entities.

At December 31, 2010, cash and cash equivalents totaled $150.7 million and approximately 121.5 million shares of common stock were outstanding.

Arena's Recent and Fourth Quarter 2010 Developments Lorcaserin

  • Received a complete response letter from the US Food and Drug Administration (FDA) regarding the lorcaserin New Drug Application (NDA), completed an end-of-review meeting with the FDA and reported on Arena and Eisai's plans related to resubmitting the NDA.
  • Announced top-line results from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial, which evaluated lorcaserin for weight management in obese and overweight patients with type 2 diabetes. Lorcaserin met the three primary efficacy endpoints, and Arena believes the results favorably support the benefit-risk profile of lorcaserin.
  • Presented at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, results from a lorcaserin mechanism of action study conducted at the Pennington Biomedical Research Center. The data showed t
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
    2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
    3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
    4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
    5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
    6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
    7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
    8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
    9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
    10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
    11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... WESTBROOK, Maine, July 25, 2014  IDEXX Laboratories, Inc. ... for the second quarter of 2014 increased 11% versus ... growth 1 for the second quarter of 2014 ... normalized for changes in distributor inventory 2 . Earnings ... 30, 2014 increased 11% from the prior year period ...
    (Date:7/25/2014)... July 25, 2014  Semler Scientific, Inc. (Nasdaq: ... risk assessment company that develops patented products that ... chronic diseases, today reported financial results for the ... 2014. "The second quarter of ... Doug Murphy-Chutorian , M.D., chief executive officer ...
    (Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
    Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3
    ... Oct. 5 The Thompson Group of Companies announced ... (AIT), a Hamilton Sundstrand Corporation business. AIT will ... Group. Financial terms of the purchase were not disclosed. ... manufacture and marketing of process analytical instruments including Analect ...
    ... CITY, Oct. 5 Orthopedics This Week , a ... Awards for Best New Technology for Spine Care in ... implant and instrument manufacturer focused on unique silicon nitride (SiN) ... in Biomaterials category for its Valeo® AL Lumbar Spacer ...
    Cached Medicine Technology:Thompson Group Acquires Hamilton Sundstrand's Applied Instrument Technologies 2Two Amedica®/US Spine® Implant Products Receive Best New Technology Awards from Orthopedics This Week 2
    (Date:7/25/2014)... (HealthDay News) -- Unlike children, the vast majority of adults ... at mealtime, according to a new study. This ... not just Americans, researchers from Cornell University revealed. They ... or improve their eating habits make better choices. "If ... stomach," researcher Brian Wansink, director of the Cornell Food ...
    (Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
    (Date:7/25/2014)... that controls when genes are switched on or off ... brain to regulate metabolism, UT Southwestern Medical Center researchers ... therapies to treat obesity and diabetes, since the transcription ... appears to influence the body,s sensitivity to insulin ... to the body,s regulation of food intake and sugar ...
    (Date:7/25/2014)... NH (PRWEB) July 25, 2014 Innerspire, ... has joined the company as a Creative Enrollment Specialist. ... extensive relationship building skills as well as his accomplished ... of small business clients, and to service the creative ... Additionally, Greg will work with small business owners ...
    (Date:7/25/2014)... American Brain Tumor Association (ABTA) today unveiled branding of ... patient and family conference in Chicago. , “This is ... we – the first and now only national organization ... tumor research – extend our reach by engaging volunteers ... our materials and services into the hands of those ...
    Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3
    ... Include 24-oz and Convenient 4-oz Travel Size Spray ... PURE ) today announced an agreement ... silver dihydrogen citrate (SDC)-based disinfectant as OneShot Plus(TM) ... Plus product line. OneShot Plus DD eliminates ...
    ... retire from BoardNATICK, Mass., March 2 Boston Scientific Corporation ... Board of Directors has elected John E. Sununu as a ... as a U.S. Senator from New Hampshire. He was ... Foreign Relations, and he was appointed the Congressional Representative to ...
    ... no harm -- from TV viewing by young children, , , MONDAY, ... a shelf full of videos claiming to be educationally stimulating for ... wallet. , A new study suggests that watching television won,t ... several hours a day. , "TV, in and of itself, ...
    ... Officially Launched to Provide Consumers a Free-of-Charge ... from Funeral Homes, Cremation Services and Cemeteries ... http://www.FuneralDecisions.com ) has announced the official launch ... tool for individuals seeking funeral, cremation, and ...
    ... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
    ... March 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ... today announced that the Company has amended the ... facility with Valens U.S. (formerly Laurus Master Funds). ... agreed to a near-term extension of this facility, ...
    Cached Medicine News:Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 2Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 3Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 4Health News:TV Watching Doesn't Fast-Track Baby's Skills 2Health News:TV Watching Doesn't Fast-Track Baby's Skills 3Health News:Taking the Stress Out of Funeral Planning, FuneralDecisions.com Offers Consumers an Innovative Approach 2Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: